We investigated the predictors of endothelial dysfunction in patients with rheumatoid arthritis (RA) by brachial artery flow-mediated vasodilatation (FMD). The study population included 50 patients with RA and 30 controls. Disease activity score (DAS28) was calculated for patients with RA. An FMD response <7% was accepted as impaired FMD. Brachial artery Doppler study revealed that in patients with RA, FMD% was significantly lower as compared with controls (6.6% ± 3.5% vs 9.7% ± 41%, P = .002). After multivariate logistic regression analysis, erythrocyte sedimentation rate (ESR; OR: 1.086, 95% confidence interval [CI]: 1.012-1.167, P = .023), duration of RA (OR: 1.392, 95% CI: 1.044-1.856, P = .024), and DAS28 (OR: 3.335, 95% CI: 1.067-10.42, P = .038) were independent predictors of impaired FMD in patients with RA. Endothelial function is impaired in patients with RA. Disease duration, DAS28, and ESR indicating active inflammation are independent predictors of impaired FMD in patients with RA.
Chatterjee AdhikariMGuinAChakrabortySSinhamahapatraPGhoshA. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum. 2012;41(5):669–675.
2.
GoodsonNMarksJLuntMSymmonsD. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis. 2005;64(11):1595–1601.
3.
SolomonDHKarlsonEWRimmEB. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303–1307.
4.
Gonzalez-GayMAGonzalez-JuanateyCMartinJ. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35(1):8–17.
5.
AgewallS. Some aspects of preventing coronary heart disease. Angiology. 2012;63(1):17–23.
6.
GuinAChatterjee AdhikariMChakrabortySSinhamahapatraPGhoshA. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum. 2013;43(1):48–54.
7.
González-JuanateyCLlorcaJGonzález-GayMA. Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther. 2011;13(3):R101.
8.
SchächingerVBrittenMBZeiherAM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899–1906.
9.
TakaseBUehataAAkimaT. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82(12):1535–1539.
10.
ArincHSarliBBaktirAO. Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis[published online July 8, 2013]. Ups J Med Sci. 2013.
11.
CharakidaMMasiSLüscherTFKasteleinJJDeanfieldJE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010;31(23):2854–2861.
12.
Gonzalez-JuanateyCTestaAGarcia-CasteloA. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003;114(8):647–652.
13.
KumedaYInabaMGotoH. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1489–1497.
14.
ArnettFCEdworthySMBlochDA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
15.
PrevooMLvan't HofMAKuperHHvan LeeuwenMAvan de PutteLBvan RielPL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48.
16.
Gonzalez-GayMAGonzalez-JuanateyCVazquez-RodriguezTRMartinJLlorcaJ. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum. 2008;38(2):67–70.
17.
JohnHKitasG. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med. 2012;23(7):575–579.
18.
WolfeFMitchellDMSibleyJT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–494.
19.
KarpouzasGAMalpesoJChoiTYLiDMunozSBudoffMJ. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease[published online July 25, 2013]. Ann Rheum Dis. 2013 Jul 25.
20.
GasparyanAYStavropoulos-KalinoglouAMikhailidisDPDouglasKMKitasGD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int. 2011;31(2):153–164.
21.
TomsTESymmonsDPKitasGD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8(3):301–326.
InciMSarliBDavarciM. Relationship between endothelial dysfunction and nocturia with benign prostatic hyperplasia[published online January 17, 2013]. Scand J Urol. 2013.
24.
SödergrenAKarpKBomanK. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther. 2010;12(4):R158.
25.
JohnHKitasGTomsTGoodsonN. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):71–82.
26.
ErbNPaceAVDouglasKMBanksMJKitasGD. Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 2004;33(5):293–299.
27.
GaziIFBoumpasDTMikhailidisDPGanotakisES. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol. 2007;25(1):102–111.
28.
CarnethonMRGulatiMGreenlandP. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. JAMA. 2005;294(23):2981–2988.
29.
BisoendialRJStroesESTakPP. Critical determinants of cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2011;17(1):21–26.
30.
BurutDFKarimYFernsGA. The role of immune complexes in atherogenesis. Angiology. 2010;61(7):679–689.
31.
KalayNAytekinMKayaMG. The relationship between inflammation and slow coronary flow: increased red cell distribution width and serum uric acid levels. Turk Kardiyol Dern Ars. 2011;39(6):463–468.
32.
MizunoYJacobRFMasonRP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb. 2011;18(5):351–358.
33.
SarliBBaktirAOSaglamH. Neutrophil-to-lymphocyte ratio is associated with severity of coronary artery ectasia. Angiology. 2014;65(2):147–151.
34.
LeeSParkYZuidemaMYHanninkMZhangC. Effects of interventions on oxidative stress and inflammation of cardiovascular diseases. World J Cardiol. 2011;3(1):18–24.
RamasamyRYanSFSchmidtAM. RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts. J Leukoc Biol. 2009;86(3):505–512.
37.
NurmohamedMT. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag. 2007;3(6):845–852.
38.
LiaoKPCaiTGainerVS. Lipid and lipoprotein levels and trends in rheumatoid arthritis compared to the general population[published online August 7, 2013]. Arthritis Care Res (Hoboken). 2013.
39.
TomsTEPanoulasVFDouglasKM. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?Angiology. 2011;62(2):167–175.
40.
RazaKBanksMKitasGD. Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol. 2005;32(4):754–756.
41.
KhattriSZandman-GoddardG. Statins and autoimmunity. Immunol Res. 2013;56(2-3):348–357.
